Navigation Links
BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores

MORRISTOWN, N.J., Nov. 28, 2012 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU) a specialty life science technology based company announced today that it has received positive test results from a global laboratory which is the world's largest private, independent research and development organization for its Ygiene Sterilant against fully virulent Bacillus anthracis Ames Spores. These tests were conducted to simulate real world contamination situations where both nonporous and porous surfaces would be present with fully virulent anthrax spores. Anthrax contaminated porous surfaces represent an especially difficult remediation testing situation. In the tests conducted, commercial carpet was used as the porous surface. The test results indicate that on the demanding carpet substrate, Ygiene IS is much more effective at eliminating anthrax spores than chlorine bleach which today is often recommended and frequently used in addressing anthrax contamination. In addition to the superior speed to kill, the Ygiene IS does not have the detrimental effect on surfaces which chlorine bleach exhibits.

BioNeutral's Chief Scientific Officer, Dr. Andy Kielbania, said, "Our Ygiene IS was specifically designed for use by the military, homeland security and first responders that need to deal with biological threats. We are extremely pleased with these results which confirm the exceptional efficacy of our Ygiene sterilants."

BioNeutral's CEO, Mark Lowenthal, stated, "These results demonstrate the uniqueness of our Ygiene IS Sterilant and will allow us to move forward in critical US government and appropriate foreign government application areas by providing the best solution to difficult problems."

About BioNeutral Group, Inc.

Headquartered in Morristown, New Jersey with lab facilities at the New Jersey Institute of Technology in Newark, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit

Find us on Facebook:

Follow us on Twitter: 

Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.


SOURCE BioNeutral Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Group Receives $400,000 in Equity Financing
2. BioNeutral Group Appoints A New Member to the Board of Directors
3. BioNeutral Group Expands The Testing Of Its Ygiene Sterilant Against Anthrax Spores
4. BioNeutral Group Appoints Mr. Mark Lowenthal as Chief Executive and President
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
7. MiMedx Group Completes $5,000,000 Private Placement
8. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
9. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
10. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
11. Statewide Network of Angel Investor Groups Announced in Alabama
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):